We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phielix et al.: Hepatic Fat Content and Adipokines

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01570660
First Posted: April 4, 2012
Last Update Posted: April 4, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
German Diabetes Center
March 14, 2012
April 4, 2012
April 4, 2012
February 2002
March 2012   (Final data collection date for primary outcome measure)
whole body insulin sensitivity [ Time Frame: within a minimal of 1 week before the start of the 12 weeks pioglitazone or glimepiride treatment and after the last day of the treatment period. ]
Participants underwent a two-step hyperinsulinemic euglycemic clamp to determine insulin sensitivity, expressed as rate of glucose disposal (Rd) in mg/kg/min.
Same as current
No Changes Posted
intrahepatocellular lipid content [ Time Frame: within a minimal of 1 week before the start of the 12 weeks pioglitazone or glimepiride treatment and after the last day of the treatment period. ]
Liver proton-magnetic resonance spectroscopy was applied to determine liver fat (HCL) in % (relative to the water peak).
Same as current
Not Provided
Not Provided
 
Phielix et al.: Hepatic Fat Content and Adipokines
Effects of Glimepiride Monotherapy Versus Combined Neteglinide-Pioglitazone Therapy on Insulin Sensitivity in Type 2 Diabetic Patients
Thiazoledinediones decrease blood glucose by their insulin-sensitizing properties. Here the investigators examined whether pioglitazone (PIO) improves insulin sensitivity independently of glycemic control and whether adipokines or non-esterfied fatty acids (NEFA) serve as mediators.
Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Type 2 Diabetes Mellitus
Drug: Pioglitazone
12 weeks of pioglitazone treatment
No Intervention: control group
parallel group without intervention
Intervention: Drug: Pioglitazone
Phielix E, Brehm A, Bernroider E, Krssak M, Anderwald CH, Krebs M, Schmid AI, Nowotny P, Roden M. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes. Diabetes Obes Metab. 2013 Oct;15(10):915-22. doi: 10.1111/dom.12112. Epub 2013 May 1.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
March 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • well controlled patients with type 2 diabetes (Hb1Ac < 8%)
  • no insulin therapy
  • no co-morbidities
  • stable medication use for the last 6 months
  • stable body weight the last 6 months
  • no diet in the last 6 months

Exclusion Criteria:

  • Hb1Ac > 8%
  • insulin therapy
  • diabetes-related co-morbidities, like cardiovascular disease, neuropathology
  • unstable medication use
  • unstable body weight in the last 6 months (> 5 kg)
  • following a diet in the last 6 months
Sexes Eligible for Study: All
45 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Austria
 
 
NCT01570660
026/2002
26/2002 ( Registry Identifier: Ethikkommisson )
No
Not Provided
Not Provided
German Diabetes Center
German Diabetes Center
Not Provided
Principal Investigator: Michael Roden, Prof. Institute for Clinical Diabetology, German Diabetes Center, D-40225, Düsseldorf, Germany; Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Department of Metabolic Diseases, Un
German Diabetes Center
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP